En vivo
FierceBiotechCity aims to lay foundation for RNAi renaissance with nearly $100M series BEndpoints News#ADA26: AstraZeneca GLP-1 pill cuts weight 10.5% after six monthsRoche MediaRoche and Nurix Therapeutics Announce Global Collaboration | PharmExec - Pharmaceutical ExecutiveBioPharma DiveCity banks nearly $100M for next-gen RNAi drugsEndpoints NewsIncyte CEO sees $2B Vega deal aiding a post-Jakafi futureClinical OMICsCortical On/Off Switch Provides Sleep Benefits to Awake MiceClinical OMICsGLP-1 Drugs Linked to Lower Rates of Substance Use DisordersEndpoints NewsCity Therapeutics gets $99M to gather data on three RNAi medicinesClinical OMICsProPure™ Endotoxin-Free Proteins for Reliable Cancer ResearchClinical OMICsTARGA Imager Enables High-Resolution Imaging of Neurodevelopmental ModelsBioPharma DiveRoche stakes $700M on Nurix’s protein-degrading drugClinical OMICsSignatera™ as a Pan-Cancer Decision-Making Tool to Illuminate the Care Pathway
FierceBiotech 24 abr 2026

After Lilly’s $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy?

After Lilly’s $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy?

Original
Contenido no disponible. Consulta la fuente original.